Diffuse large B-cell lymphoma trials in United States

In United States 131 Also abroad 346

131 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Where
Atlanta, Louisville, New York
Age
18 years and over
People
32 worldwide
Run by
Ranok Therapeutics (Hangzhou) Co., Ltd.
See details and how to joinNCT05487170
Phase 2Taking people
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Where
Pittsburgh
Age
18 years to 79 years
People
30
Run by
John Lister
See details and how to joinNCT05281809
Phase 2Taking people
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Where
Chapel Hill, Hackensack, New York, Rochester, Salt Lake City, St Louis
Age
18 years and over
People
120
Run by
Academic and Community Cancer Research United
See details and how to joinNCT06238648
No phaseTaking people
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
Where
Palo Alto
Age
18 years and over
People
300
Run by
Adaptive Biotechnologies
See details and how to joinNCT05255354
Phase 2Taking people
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Atlanta, Boca Raton, Canton, Fountain Valley, Greenville, Hollywood, Indianapolis, New Orleans, Omaha, Pittsburgh, Plantation, Santa Fe, St. Petersburg, Toledo, Watertown, West Reading
Age
18 years and over
People
102 worldwide
Run by
ImmunoVaccine Technologies, Inc. (IMV Inc.)
See details and how to joinNCT04920617
Phase 1/2Taking people
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Where
Cincinnati, Columbus, Dallas, Goshen
Age
18 years and over
People
84 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT04502394